Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04644237
Title Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Daiichi Sankyo, Inc.
Indications

lung non-small cell carcinoma

Therapies

Trastuzumab deruxtecan

Age Groups: senior | adult
Covered Countries USA | CAN

Additional content available in CKB BOOST